Market Research Logo

China Pharmaceuticals & Healthcare Q4 2019

China Pharmaceuticals & Healthcare Q4 2019

Key View:

China will continue to benefit from significant investment from the innovative pharmaceutical industry. While theChinese pharmaceutical market continues to face uncertainty on the back of challenges around drug pricing and the low levels ofintellectual property protection, we maintain our view that it presents one of the most attractive investment destinations in the AsiaPacific region. Underpinning this view, China boasts a number of inherent advantages that makes it well positioned for continuedFDI flows into the pharmaceutical sector. These include: a rapidly ageing population, a well-established manufacturing industry forpharmaceuticals and notable government commitment to sector development.


Key View
SWOT
Industry Forecast
Pharmaceutical Market Forecast
Healthcare Market Forecast
Prescription Drug Market Forecast
Patented Drug Market Forecast
Generic Drug Market Forecast
OTC Medicine Market Forecast
Pharmaceutical Trade Forecast
Industry Risk/Reward Index
Asia Pacific Innovative Pharmaceuticals Risk/Reward Index
Innovative Pharmaceuticals Risk/Reward Index
Regulatory Development
Regulatory Review
13th Five-Year Plan: Key Points
Market Overview
Competitive Landscape
Company Profile
AstraZeneca
Bayer HealthCare
China Shijiazhuang Pharmaceutical Group (CSPC)
Eli Lilly (Lilly China)
GlaxoSmithKline
MSD
Merck KGaA
North China Pharmaceutical Corporation
Novartis
Pfizer
Roche
Sanofi
Shanghai Pharmaceuticals Holding Co
Sinopharm
China Demographic Outlook
Pharmaceuticals & Healthcare Glossary
Pharmaceuticals & Healthcare Methodology

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report